- Home
- IMUX vs CODA Comparison
IMUX vs CODA Comparison
Compare IMUX & CODA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | CODA |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 98.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMUX | CODA |
|---|---|---|
| Price | $0.52 | $9.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 54.3K |
| Earning Date | 02-14-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.09 |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | ★ $24,347,217.00 |
| Revenue This Year | N/A | $30.82 |
| Revenue Next Year | N/A | $20.84 |
| P/E Ratio | ★ N/A | $31.00 |
| Revenue Growth | N/A | ★ 29.34 |
| 52 Week Low | $0.51 | $5.76 |
| 52 Week High | $1.39 | $10.54 |
Technical Indicators
Market Signals| Indicator | IMUX | CODA |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 53.30 |
| Support Level | $0.51 | $8.80 |
| Resistance Level | $0.60 | $9.60 |
| Average True Range (ATR) | 0.04 | 0.43 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 9.03 | 50.56 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About CODA Coda Octopus Group Inc.
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.